Drugs List

Therapeutic Indications

Uses

Constipation in terminally ill patients

Contraindications

Abdominal pain of unknown cause
Infants in nappies
Appendicitis
Breastfeeding
Gastrointestinal obstruction
Hereditary fructose intolerance
Inflammatory bowel disease
Pregnancy
Severe dehydration

Precautions and Warnings

Children under 12 years
Alcoholism
Epileptic disorder
Faecal incontinence
Hepatic disorder

Advise patient ability to drive or operate machinery may be impaired
Not all available brands are licensed for use in children under 12 years
Restricted use - terminally ill patients only
Contains alcohol
Contains parabens
Oral liquid contains propylene glycol
Presentations with sorbitol unsuitable in hereditary fructose intolerance
Avoid prolonged contact with skin
Risk of adenocarcinoma of the bowel and liver
May colour urine red
Not for long term use

In the presence of renal failure or insufficiency, hypermagnesemia may occur.

Concurrent use with a stool softener laxative may enhance the systemic absorption of dantron.

Pregnancy and Lactation

Pregnancy

Co-danthramer is contraindicated during pregnancy.

Use of co-danthramer during pregnancy is contraindicated by the manufacturer.

Rodent studies indicate potential carcinogenic risk. At the time of writing there is limited human data available. Risks are unknown.

Lactation

Co-danthramer is contraindicated during breastfeeding.

Use of co-danthramer when breastfeeding is contraindicated by the manufacturer.

Dantron is excreted in breast milk. The risk to humans is unknown.

Side Effects

Abdominal cramps
Discolouration of mucosa of the large intestine
Rash
Red colouring of perianal skin
Red urine
Sloughing of tissue
Tiredness
Weakness

Presentation

Oral formulations of co-danthramer.

Drugs List

Therapeutic Indications

Uses

Constipation in terminally ill patients

Dosage

Adults

Children

Contraindications

Abdominal pain of unknown cause
Infants in nappies
Appendicitis
Breastfeeding
Gastrointestinal obstruction
Hereditary fructose intolerance
Inflammatory bowel disease
Pregnancy
Severe dehydration

Precautions and Warnings

Children under 12 years
Alcoholism
Epileptic disorder
Faecal incontinence
Hepatic disorder

Advise patient ability to drive or operate machinery may be impaired
Not all available brands are licensed for use in children under 12 years
Restricted use - terminally ill patients only
Contains alcohol
Contains parabens
Oral liquid contains propylene glycol
Presentations with sorbitol unsuitable in hereditary fructose intolerance
Avoid prolonged contact with skin
Risk of adenocarcinoma of the bowel and liver
May colour urine red
Not for long term use

In the presence of renal failure or insufficiency, hypermagnesemia may occur.

Concurrent use with a stool softener laxative may enhance the systemic absorption of dantron.

Pregnancy and Lactation

Pregnancy

Co-danthramer is contraindicated during pregnancy.

Use of co-danthramer during pregnancy is contraindicated by the manufacturer.

Rodent studies indicate potential carcinogenic risk. At the time of writing there is limited human data available. Risks are unknown.

Lactation

Co-danthramer is contraindicated during breastfeeding.

Use of co-danthramer when breastfeeding is contraindicated by the manufacturer.

Dantron is excreted in breast milk. The risk to humans is unknown.

Side Effects

Abdominal cramps
Discolouration of mucosa of the large intestine
Rash
Red colouring of perianal skin
Red urine
Sloughing of tissue
Tiredness
Weakness

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Further Information

Last Full Review Date: January 2020

Reference Sources

Summary of Product Characteristics: Co-Danthramer 25mg/200mg per 5ml Oral Suspension. Pinewood Healthcare. Revised July 2019.

Summary of Product Characteristics: Co-Danthramer 75mg/1000mg per 5ml Oral Suspension. Pinewood Healthcare. Revised July 2019.

NICE Evidence Services Available at: www.nice.org.uk Last accessed: 16 January 2020